Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
June 24 2022 - 9:00AM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage
precision oncology company designing and developing novel targeted
therapies for cancer treatment, and The University of Texas MD
Anderson Cancer Center today announced a strategic research and
development alliance to expand the evaluation of two of Turning
Point's investigational small molecules focusing on precision
medicine targets well known in oncology.
The initial focus of the alliance will be Turning Point’s lead
drug candidate, repotrectinib, a next-generation kinase inhibitor
targeting the ROS1 and NTRK oncogenic drivers of non-small cell
lung cancer and advanced solid tumors that is currently being
studied in a registrational Phase 1/2 study (TRIDENT-1). Alliance
studies also will include elzovantinib (TPX-0022), a kinase
inhibitor targeting MET, CSF1R and SRC, which is currently being
studied in a Phase 1 trial of patients with advanced solid tumors
harboring genetic alterations in MET (SHIELD-1).
The planned focus of the alliance will include monotherapy and
potential combinations with other agents – including chemotherapy,
immunotherapies and other targeted agents.
"This agreement embodies our commitment to further advancing our
innovative macrocyclic programs and complementing our development
efforts through collaborative alliances with those who share our
vision for breakthrough science," said Homa Yeganegi, Senior Vice
President and Global Product Development Lead at Turning Point
Therapeutics. "We look forward to working with MD Anderson to
strengthen our scientific and clinical understanding of our
multi-targeted compounds in several tumor types with the goal of
speeding delivery of new cancer treatments to patients."
The alliance brings together MD Anderson's clinical trial
infrastructure and expertise with Turning Point's differentiated
targeted oncology pipeline. Under the terms of the alliance’s
agreement, which spans a five-year period, collaborative
preclinical and clinical studies will be conducted in several solid
tumors, including non-small cell lung cancers, gastrointestinal
malignancies and endocrine cancers.
“There is a major unmet need to develop effective
next-generation targeted therapies for cancer patients with
oncogene-driven solid tumors, particularly those with mutations
that render them resistant to our current therapies,” said John V.
Heymach, M.D., Ph.D., Chair of Thoracic/Head & Neck Medical
Oncology at MD Anderson. "Our alliance with Turning Point
represents an important opportunity to work toward advancing new
treatment options for patients using novel inhibitors that target
multiple driver mutations with the most characterized resistance
patterns in common cancers."
The collaborative studies will be overseen by a joint steering
committee. Turning Point will provide funding, study materials and
other ongoing support throughout the term of the alliance.
About MD AndersonThe University of Texas MD
Anderson Cancer Center in Houston ranks as one of the world's most
respected centers focused on cancer patient care, research,
education and prevention. The institution’s sole mission is to end
cancer for patients and their families around the world. MD
Anderson is one of only 52 comprehensive cancer centers designated
by the National Cancer Institute (NCI). MD Anderson is No. 1
for cancer in U.S. News & World Report’s “Best Hospitals”
rankings. It has been named one of the nation’s top two hospitals
for cancer since the rankings began in 1990. MD Anderson receives a
cancer center support grant from the NCI of the National Institutes
of Health (P30 CA016672).
About Turning Point Therapeutics Inc.Turning
Point Therapeutics is a clinical-stage precision oncology company
with a pipeline of investigational drugs designed to address key
limitations of existing cancer therapies. The company’s lead drug
candidate, repotrectinib, is a next-generation kinase inhibitor
targeting the ROS1 and TRK oncogenic drivers of non-small cell lung
cancer and advanced solid tumors. Repotrectinib, which is being
studied in a registrational Phase 2 study in adults and a Phase 1/2
study in pediatric patients, has shown antitumor activity and
durable responses among kinase inhibitor treatment-naïve and
pre-treated patients. The company’s pipeline of drug candidates
also includes elzovantinib, targeting MET, CSF1R and SRC, which is
being studied in a Phase 1 trial of patients with advanced or
metastatic solid tumors harboring genetic alterations in MET;
TPX-0046, targeting RET, which is being studied in a Phase 1/2
trial of patients with advanced or metastatic solid tumors
harboring genetic alterations in RET; TPX-0131, a next-generation
ALK inhibitor, which is being studied in a Phase 1/2 trial of
previously treated patients with ALK-positive advanced or
metastatic non-small cell lung cancer; and TPX-4589 (LM-302), a
novel ADC targeting Claudin18.2 which is being studied in a Phase 1
study in gastrointestinal cancers. The company is driven to develop
therapies that mark a turning point for patients in their cancer
treatment. For more information, visit www.tptherapeutics.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“plans,” “will,” “believes,” “anticipates,” “expects,” “intends,”
“goal,” “potential” and similar expressions are intended to
identify forward-looking statements. Such forward-looking
statements include statements regarding, among other things,
Turning Point Therapeutics’ ability to advance its macrocyclic
programs and speed delivery of new cancer treatments to patients.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. These forward-looking
statements are based upon Turning Point Therapeutics’ current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, risks and uncertainties associated with Turning Point
Therapeutics’ business in general, risks and uncertainties related
to the impact of the COVID-19 pandemic to Turning Point
Therapeutics’ business and the other risks described in Turning
Point Therapeutics’ filings with the Securities and Exchange
Commission (SEC), including its quarterly report on Form 10-Q filed
with the SEC on May 10, 2022. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Turning Point Therapeutics undertakes no obligation
to update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Contact: Adam D. Levy, Ph.D., MBA
ir@tptherapeutics.com858-867-6366
Clayton Boldt, Ph.D.CRBoldt@MDAnderson.org713-792-9518
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Jul 2023 to Jul 2024